-
- Sign In
- Tests
-
Invitae testsFollow-up testingFrequently ordered panels
- How to order
-
Getting startedEssentialsSponsored programs
- Resources
-
Clinical resourcesEducational materialsWorking together
- Technology
-
Our technologyA new gold standardData sharing
- FAQ
- FOR PATIENTS
- CONTACT
- FAQs / SUPPORT
NIPA1
Alias
FSP3; SPG6
Associated disorders
The NIPA1 gene is associated with autosomal dominant hereditary spastic paraplegia 6 (SPG6) (MedGen UID: 324965).
Order single gene
NIPA1
Order this gene as a single gene test.
Order a test
Invitae tests that include this gene:
Clinical sensitivity
The percentage of hereditary spastic paraplegia attributed to pathogenic variants identified in NIPA1 is unknown.
Gene function
The NIPA1 gene encodes a magnesium transporter protein that associates with early endosomes and the cell surface in a variety of neuronal and epithelial cells. This protein may play a role in nervous system development and maintenance.
References
- Tsang, HT, et al. The hereditary spastic paraplegia proteins NIPA1, spastin and spartin are inhibitors of mammalian BMP signalling. Hum. Mol. Genet. 2009; 18(20):3805-21. doi: 10.1093/hmg/ddp324. PMID: 19620182
- Fink, JK. Hereditary Spastic Paraplegia Overview. 2000 Aug 15. In: Pagon, RA, et al, editors. GeneReviews (Internet). University of Washington, Seattle; Available from: http://www.ncbi.nlm.nih.gov/books/NBK1509/ PMID: 20301682
- Rainier, S, et al. NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). Am. J. Hum. Genet. 2003; 73(4):967-71. doi: 10.1086/378817. PMID: 14508710
- Chen, S, et al. Distinct novel mutations affecting the same base in the NIPA1 gene cause autosomal dominant hereditary spastic paraplegia in two Chinese families. Hum. Mutat. 2005; 25(2):135-41. doi: 10.1002/humu.20126. PMID: 15643603
Assay
Assay and technical information
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence in the transcript listed below. In addition, analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any specific limitations in the analysis of these genes are also listed in the table below.
Our analysis detects most intragenic deletions and duplications at single exon resolution. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. If you are requesting the detection of a specific single-exon copy number variation, please contact Client Services before placing your order.
| Gene | Transcript reference | Sequencing analysis | Deletion/Duplication analysis |
|---|---|---|---|
| NIPA1 | NM_144599.4 |
Resources
Patient resources
Patient guide: Genetic testing simplifiedReferences
- Tsang, HT, et al. The hereditary spastic paraplegia proteins NIPA1, spastin and spartin are inhibitors of mammalian BMP signalling. Hum. Mol. Genet. 2009; 18(20):3805-21. doi: 10.1093/hmg/ddp324. PMID: 19620182
- Fink, JK. Hereditary Spastic Paraplegia Overview. 2000 Aug 15. In: Pagon, RA, et al, editors. GeneReviews (Internet). University of Washington, Seattle; Available from: http://www.ncbi.nlm.nih.gov/books/NBK1509/ PMID: 20301682
- Rainier, S, et al. NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). Am. J. Hum. Genet. 2003; 73(4):967-71. doi: 10.1086/378817. PMID: 14508710
- Chen, S, et al. Distinct novel mutations affecting the same base in the NIPA1 gene cause autosomal dominant hereditary spastic paraplegia in two Chinese families. Hum. Mutat. 2005; 25(2):135-41. doi: 10.1002/humu.20126. PMID: 15643603
